Back to Browse Journals » ClinicoEconomics and Outcomes Research » Volume 4

Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada

Authors Tarride JE, Haq M, Taylor VH, Sharma AM, Nakhai-Pour HR,  O'Reilly D, Xie F, Dolovich L, Goeree R

Published Date January 2012 Volume 2012:4 Pages 21—30

DOI http://dx.doi.org/10.2147/CEOR.S24192

Received 13 July 2011, Accepted 14 October 2011, Published 24 January 2012

Jean-Eric Tarride1,2, Mahbubul Haq1, Valerie H Taylor3, Arya M Sharma4, Hamid Reza Nakhai-Pour1, Daria O’Reilly1,2, Feng Xie1,2, Lisa Dolovich2,5,6, Ron Goeree1,2
1Programs for Assessment of Technology in Health (PATH) Research Institute, St Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; 3Department of Psychiatry, University of Toronto, Ontario, Canada; 4Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; 5Centre for Evaluation of Medicines, St Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada; 6Department of Family Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada

Background: Obesity is today’s principal neglected public health problem, as a rising proportion of adults will succumb to the medical complications of obesity. However, little is known about the burden of obesity in adults living in Ontario.
Objectives: To present an overview of the human and economic burden associated with BMI categories in Ontario, Canada, in terms of socio-demographics, comorbidities, health-related quality of life (HRQoL) and costs associated with hospitalization, same day procedures and physician visits.
Methods: The records of all Ontarians who participated in the Canadian Community Health Survey (CCHS), cycle 1.1 and provided consent to data linkage were linked to three administrative databases. Socio-demographic variables, medical characteristics, HRQoL, one year hospitalization, day procedure and physician costs were described per BMI category. Regression analyses were conducted to identify predictors of medical characteristics, HRQoL and costs.
Results: More than 50% of adult participants were either overweight or obese in 2000/2001. Obese adults, and to a lesser extent overweight adults, were more likely to report physician-diagnosed comorbid conditions, to use medications, and to have a lower HRQoL. After covariate adjustment, the hospitalization and physician costs were respectively 40% and 22% higher among obese and overweight adults than among normal-weight adults. No statistical cost differences were observed between normal and underweight individuals or between normal and overweight individuals. HRQoL was significantly lower in underweight and obese adults when compared to normal-weight individuals.
Conclusions: Due to the large human and economic burden associated with under- or excess-weight, policies promoting healthy weight should remain a priority for governments and employers.

Keywords: health-related quality of life, costs, body mass index categories, Ontario

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents

Tarride JE, Burke N, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R

ClinicoEconomics and Outcomes Research 2012, 4:287-298

Published Date: 4 October 2012

Readers of this article also read:

Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice

Bramlage P, Fronk EM, Wolf WP, Smolnik R, Sutton G, Schmieder RE

Vascular Health and Risk Management 2015, 11:1-8

Published Date: 17 December 2014

Magnetic field enhanced convective diffusion of iron oxide nanoparticles in an osmotically disrupted cell culture model of the blood–brain barrier

Sun Z, Worden M, Wroczynskyj Y, Yathindranath V, van Lierop J, Hegmann T, Miller DW

International Journal of Nanomedicine 2014, 9:3013-3026

Published Date: 20 June 2014

In situ precipitation: a novel approach for preparation of iron-oxide magnetoliposomes

Xia S, Li P, Chen Q, Armah M, Ying X, Wu J, Lai J

International Journal of Nanomedicine 2014, 9:2607-2617

Published Date: 23 May 2014

Green synthesis of silver nanoparticles by Chrysanthemum morifolium Ramat. extract and their application in clinical ultrasound gel

He Y, Du ZY, Lv HB, Jia QF, Tang ZK, Zheng X, Zhang K, Zhao FH

International Journal of Nanomedicine 2013, 8:1809-1815

Published Date: 7 May 2013

Glaucoma associated with the management of rhegmatogenous retinal detachment

Mangouritsas G, Mourtzoukos S, Portaliou DM, Georgopoulos VI, Dimopoulou A, Feretis E

Clinical Ophthalmology 2013, 7:727-734

Published Date: 15 April 2013

Bioavailability of nanoemulsified conjugated linoleic acid for an antiobesity effect

Kim D, Park JH, Kweon DJ, Han GD

International Journal of Nanomedicine 2013, 8:451-459

Published Date: 4 February 2013

Cellular interaction of folic acid conjugated superparamagnetic iron oxide nanoparticles and its use as contrast agent for targeted magnetic imaging of tumor cells

Kumar M, Singh G, Arora V, Mewar S, Sharma U, Jagannathan NR, Sapra S, Dinda AK, Kharbanda S, Singh H

International Journal of Nanomedicine 2012, 7:3503-3516

Published Date: 6 July 2012

Hereditary diffuse gastric cancer: genetics, prophylactic total gastrectomy, and follow up

Shenoy S, Palmer C, Dunsworth T, McNatt S

Gastrointestinal Cancer: Targets and Therapy 2011, 1:15-19

Published Date: 18 April 2011